A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
Background: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority. MVA85A is a candidate tuberculosis vaccine designed to enhance immunity to the existing vaccine, Bacillus Calmett...
المؤلفون الرئيسيون: | Rowland, R, Brittain, N, Poulton, I, Minassian, A, Sander, C, Porter, D, Williams, N, Satti, I, Pathan, A, Lawrie, A, McShane, H |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Elsevier
2012
|
مواد مشابهة
-
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
حسب: Pathan, A, وآخرون
منشور في: (2012) -
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
حسب: Pathan, A, وآخرون
منشور في: (2012) -
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
حسب: Whelan, K, وآخرون
منشور في: (2009) -
Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
حسب: Harris, S, وآخرون
منشور في: (2011) -
DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
حسب: Mcshane, H
منشور في: (2008)